<DOC>
	<DOC>NCT01417091</DOC>
	<brief_summary>This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI). Pharmacodynamic effect will be determined by serological biomarkers and radiologic assessments. In addition, tolerability and pharmacokinetics (PK) will be evaluated. Twelve to 15 patients will be enrolled.</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<criteria>Osteogenesis imperfecta Two or more previous fractures Bone mineral density Zscore of â‰¤ 1.0 and &gt; 4.0 Open epiphyses Fracture within last 2 weeks Treatment with bisphosphonates/teriparatide (last 6 months) Surgery within last year Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Brittle bone disease</keyword>
	<keyword>inherited</keyword>
	<keyword>connective tissue disorder</keyword>
	<keyword>fracture</keyword>
</DOC>